1	2	3	4	5	6
9	Jammu & Kashmir	NA	NA	17.6	NA
10	Karnataka	24.1	62	55.6	2.9
11	Kerala	18.0	13	46.7	1.7
12	Madhya Pradesh	33.2	99	47.4	4.2
13	Maharashtra	24.5	55	51.0	2.9
14	Manipur	20.6	27+	23.7	NA
15	Meghalaya	29.0	45+	4.0	NA
16	Mizoram	NA	NA	44.2	NA
17	Nagaland	20.1*	6+	8.1	NA
18	Orissa	27.8	103	39.5	3.1
19	Punjab	21.6	54	76.9	3.3
20	Rajasthan	33.3	86	32.6	4.3
21	Sikkim	22.5	47+	23.7	NA
22	Tamil Nadu	20.5	54	51.7	2.1
23	Tripura	18.9	45+	26.3	NA
24	Uttar Pradesh	31.5	86	37.2	5.2
25	West Bengal	23.6	58	34.2	3.8
	Union Territories				
1	Andaman and Nicobar Islands	18.7	32+	40.9	NA
2	Chandigarh	19.5	42+	38.3	NA
3	Dadra and Nagar Haveli	29.7	73+	35.6	NA
4	Daman and Diu	21.8	36+	36.8	NA
	Delhi	23.3	39+	33.9	NA
	Lakshadweep	25.5	37+	9.6	NA
7	Pondicherry	20.1	25+	65.7	NA

Source : Col (3) and (4), Sample Registration System (SRS) data for 1995. Col (6) SRS data for 1993. (Col (5) Programme Data.

NA : Not Available.

* : Figures related to SRS 1994.

\+ : Three-year moving average (1993—95).

Marketing of new diabetes drug

2532. **SYED SIBTEY RAZI:** Will the **PRIME MINISTER** be pleased to state:

(a) whether Government are aware that marketing of new diabetes drug by Warner-Lambert Co. in the U.S.A. by Pfizer Inc. and by Glaxo welcome in Europe, offers 'dramatic' results and could actually prevent the disease in patients at risk;

(b) whether manufacturers of the medicine referred to in part (a) above also claim that it would be

to improve the body's sensitivity to insulin;

(c) whether Government propose to get the efficacy of the drug studied and get it marketed in the country in the near future; and

(d) if so, the details thereof and if not, the reasons therefor?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (SHRIMATI RENUKA CHOWDHURY): (a) and (b) The new drug Troglitazone, said to be marketed by M/s Warner lambert Co. in U.S.A.; by M/s Pfizer Inc. and by M/s Glaxo — Welcome in Europe, is reported to help improve the body's sensitivity to insulin. Troglitazone is claimed to be a first in a new class of drugs known as Asthiazolidinediones which reduce insulin resistance. It is indicated for type II diabetes where blood sugar is inadequately controlled by insulin therapy.

(c) and (d) No application has been filed by any firm with Drug Controller (India) to market the said drug in the country.

Supply of old mother tincture in CGHS

2533 SHRI GHUFRAN AZAM: Will the PRIME MINISTER be pleased to state:

(a) what is the life span of homoeopathic Mother Tincture;

(b) whether the Mother Tincture supplied by M/s. Shiv Shankar, manufactured in the year 1988, can be used safely;

(c) if not, how few CGHS Homoeopathic Dispensaries in Delhi are supplying that Mother Tincture to the beneficiaries;

(d) whether most of the 15 ml phials of Mother Tincture supplied by M/s. Shiv Shankar are found half or quarter filled; and

(e) if so, the details thereof?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (SHRIMATI RENUKA CHOWDHURY): (a) to (c) Under the Drugs and Cosmetic Act & Rules thereunder, no "Shelf-life" is assigned to homoeopathic medicines, including Mothers Tincture.

Mother Tincture is purchased after checking its quality.

(d) and (e) In so far as this particular supplier is concerned, there have been instances of sub-standard supply which has resulted in deregistration of the firm from the CGHS rate contract. Action to effect recovery has been initiated.

Posting and transfer criteria in ISM & H

2534. SHRI GHUFRAN AZAM: Will the PRIME MINISTER be pleased to state:

(a) what are the criteria for post- and transfer to the posts of Advisor, Deputy Advisor, Assistant Advisors and Research Officers in the Department of Indian System of Medicines and Homoeopathy (ISM & H);

(b) whether the posts are interchangeable with CGHS and different Goverement Laboratories;

(c) if so, how many doctors have been transferred from ISM&H to CGHS and different Laboratories during the last three years; and

(d) whether Government intand to maintain the similar transfer and posting policy in the Department of ISM&H in future also?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (SHRIMATI RENUKA CHOWDHURY): (a) The criteria for posting and trans-